Literature DB >> 30870223

Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer: Is It Really More Dangerous?

Angelita Habr-Gama1,2, Guilherme Pagin São Julião1, Bruna Borba Vailati1, Laura M Fernandez1, Cinthia D Ortega3, Nuno Figueiredo4, Joaquim Gama-Rodrigues1,2, Rodrigo Oliva Perez1,2,5.   

Abstract

BACKGROUND: Select patients with complete clinical response to chemoradiation have been managed without radical surgery. The presence of radiologic evidence of nodal metastases at baseline could be a risk factor for local tumor regrowth, more advanced stage at the time of recurrence, and worse distant metastases-free survival.
OBJECTIVE: The purpose of this study was to compare the outcomes of patients with baseline node-positive and node-negative cancer after neoadjuvant chemoradiation and complete clinical response managed nonoperatively.
DESIGN: This was a retrospective review of consecutive patients with nonmetastatic distal rectal cancer undergoing neoadjuvant chemoradiation. PATIENTS: Consecutive patients with clinical and radiologic evidence of complete clinical response at 8 to 10 weeks were managed nonoperatively and enrolled in a strict follow-up program (watch and wait). Patients with incomplete clinical response or tumor regrowth after initial complete clinical response were referred to surgery. MAIN OUTCOMES MEASURES: Surgery-free and distant metastases-free survival were compared between patients according to nodal status at baseline.
RESULTS: A total of 117 patients with node-positive and 218 with node-negative cancer at baseline were reviewed. Overall, 62 (53.0%; node positive) and 135 (61.9%; node negative) achieved a complete clinical response and were managed nonoperatively (p = 0.13). Patients with baseline node-positive cancer had similar rates of pathologic nodal metastases at the time of recurrence. Five-year surgery-free (39.7% vs 46.8%; p = 0.2) and distant metastases-free survival (77.5% vs 80.5%; p = 0.49) were similar between baseline node-positive and node-negative patients. LIMITATIONS: This was a retrospective study with a small sample size and possible inaccurate nodal staging.
CONCLUSIONS: Patients with rectal cancer with node-positive cancer at baseline who develop a complete clinical response after neoadjuvant chemoradiation are not at increased risk for local tumor regrowth or development of more advanced disease at the time of recurrence. These patients seem to be safe candidates for organ-preserving strategies after achieving complete clinical response. See Video Abstract at http://links.lww.com/DCR/A902.

Entities:  

Mesh:

Year:  2019        PMID: 30870223     DOI: 10.1097/DCR.0000000000001337

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

Review 1.  Nonoperative Management for Rectal Cancer.

Authors:  Felipe F Quezada-Diaz; J Joshua Smith
Journal:  Hematol Oncol Clin North Am       Date:  2022-05-11       Impact factor: 2.861

Review 2.  Current Status of the Management of Stage I Rectal Cancer.

Authors:  Craig Howard Olson
Journal:  Curr Oncol Rep       Date:  2020-04-02       Impact factor: 5.075

3.  Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent.

Authors:  Reena Engineer; Avanish Saklani; Ashwin D'souza; Supreeta Arya; Suman Kumar; Vikas Ostwal; Anant Ramaswamy; Supriya Chopra; Prachi Patil
Journal:  Indian J Surg Oncol       Date:  2021-09-09

Review 4.  Role of magnetic resonance imaging in organ-preserving strategies for the management of patients with rectal cancer.

Authors:  Cinthia D Ortega; Rodrigo O Perez
Journal:  Insights Imaging       Date:  2019-05-30

5.  MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology.

Authors:  Seong Ho Park; Seung Hyun Cho; Sang Hyun Choi; Jong Keon Jang; Min Ju Kim; Seung Ho Kim; Joon Seok Lim; Sung Kyoung Moon; Ji Hoon Park; Nieun Seo
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

6.  Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer.

Authors:  Mariana F Coraglio; Martin A Eleta; Mirta R Kujaruk; Javier H Oviedo; Enrique L Roca; Guillermo A Masciangioli; Guillermo Mendez; Ilma S Iseas
Journal:  World J Surg Oncol       Date:  2020-11-30       Impact factor: 2.754

7.  GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer.

Authors:  Alexandra J Stewart; Evert J Van Limbergen; Jean-Pierre Gerard; Ane L Appelt; Frank Verhaegen; Maaike Berbee; Te Vuong; Ciarna Brooker; Tim Rockall; Arthur Sun Myint
Journal:  Clin Transl Radiat Oncol       Date:  2021-12-11

8.  T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.

Authors:  Ian P Hayes; Elasma Milanzi; Rachel M Pelly; Peter Gibbs; Jeanette C Reece
Journal:  J Surg Oncol       Date:  2022-05-30       Impact factor: 2.885

9.  Associations between clinical characteristics and tumor response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Xiaolin Pang; Yuanhong Gao; Hanchen Yi; Hailing Liu; Shuai Liu; Jian Zheng
Journal:  Cancer Med       Date:  2021-06-15       Impact factor: 4.452

Review 10.  The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Authors:  Fatima Domenica Elisa De Palma; Gaetano Luglio; Francesca Paola Tropeano; Gianluca Pagano; Maria D'Armiento; Guido Kroemer; Maria Chiara Maiuri; Giovanni Domenico De Palma
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.